MedTrace Logo

Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses (CIRCA-HPV)

NCT03739775 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2025-09-15

No results posted yet for this study

Summary

ctDNA detection in patients with previously treated, HPV-induced, stage II or III invasive pelvic cancer and who are currently in post-treatment follow-up.

Conditions

  • HPV Positive Pelvic Cancer

Interventions

PROCEDURE

Blood sampling

Patients will have a blood draw at each visit to the hospital and at least 6 months (+/- 1 month) intervals.

Sponsors & Collaborators

  • Institut Curie

    lead OTHER

Principal Investigators

  • François-Clément BIDARD, PhD · Institut Curie Paris

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-24
Primary Completion
2026-06-01
Completion
2026-06-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03739775 on ClinicalTrials.gov